Search
Search titles only
By:
Search titles only
By:
Home
Forums
New posts
Search forums
What's new
New posts
New profile posts
Latest activity
Members
Current visitors
New profile posts
Search profile posts
Log in
Register
Search
Search titles only
By:
Search titles only
By:
New posts
Search forums
Menu
Install the app
Install
Reply to Thread
Guest, we'd love to know what you think about the forum! Take the
Diabetes Forum Survey 2025 »
Home
Forums
Diabetes News and Research
Diabetes News
US approves Farxiga to reduce heart failure hospitalisation risk for people with type 2...
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Message
<blockquote data-quote="DCUK NewsBot" data-source="post: 2156476" data-attributes="member: 106455"><p>Dapagliflozin (Farxiga) has been approved in the US as a treatment to reduce the risk of hospitalisation for heart failure. The US Food and Drug Administration (FDA) approved this specific use of the drug for people with type 2 diabetes that have either established cardiovascular disease or a number of cardiovascular risk factors. Made by AstraZeneca, Farxiga is a sodium glucose co-transporter 2 (SGLT2) inhibitor medication. These medications help the kidneys to filter more glucose out of the blood, allowing the excess glucose to be passed out of the body via urine. In the UK, dapagliflozin is prescribed under the slightly different name of Forxiga. The decision to approve the drug comes nearly a year after results from the DECLARE-TIMI 58 trial, involving over 17,000 people, was published. The study showed significantly lower rates of hospitalisation for heart failure in people taking dapagliflozin compared with those taking a placebo. Lead researcher Dr Stephen Wiviott, from Brigham and Women's Hospital and Harvard Medical School, said: "DECLARE-TIMI 58 is a landmark trial, offering compelling evidence that dapagliflozin can reduce the risk of heart failure in patients living with type 2 diabetes with multiple risk factors for or established cardiovascular disease. "These data could help change the way we approach diabetes management; going beyond a singular focus on glucose control to help address the risk of heart failure in a diverse population of patients." The results of the DECLARE-TIMI 58 trial showed that people with type 2 diabetes and at risk of atherosclerotic cardiovascular disease had a 17% lower risk of hospitalisation for heart failure than those assigned to receive placebo. The trial showed no significant differences, between dapagliflozin and placebo, in the risks of major adverse cardiovascular events (MACE) such as heart disease, stroke from blood clots or death from cardiovascular disease.</p><p></p><p><a href="http://www.diabetes.co.uk/news/2019/oct/us-approves-farxiga-to-reduce-heart-failure-hospitalisation-risk-for-people-with-type-2-diabetes-97298463.html" target="_blank">Continue reading...</a></p></blockquote><p></p>
[QUOTE="DCUK NewsBot, post: 2156476, member: 106455"] Dapagliflozin (Farxiga) has been approved in the US as a treatment to reduce the risk of hospitalisation for heart failure. The US Food and Drug Administration (FDA) approved this specific use of the drug for people with type 2 diabetes that have either established cardiovascular disease or a number of cardiovascular risk factors. Made by AstraZeneca, Farxiga is a sodium glucose co-transporter 2 (SGLT2) inhibitor medication. These medications help the kidneys to filter more glucose out of the blood, allowing the excess glucose to be passed out of the body via urine. In the UK, dapagliflozin is prescribed under the slightly different name of Forxiga. The decision to approve the drug comes nearly a year after results from the DECLARE-TIMI 58 trial, involving over 17,000 people, was published. The study showed significantly lower rates of hospitalisation for heart failure in people taking dapagliflozin compared with those taking a placebo. Lead researcher Dr Stephen Wiviott, from Brigham and Women's Hospital and Harvard Medical School, said: "DECLARE-TIMI 58 is a landmark trial, offering compelling evidence that dapagliflozin can reduce the risk of heart failure in patients living with type 2 diabetes with multiple risk factors for or established cardiovascular disease. "These data could help change the way we approach diabetes management; going beyond a singular focus on glucose control to help address the risk of heart failure in a diverse population of patients." The results of the DECLARE-TIMI 58 trial showed that people with type 2 diabetes and at risk of atherosclerotic cardiovascular disease had a 17% lower risk of hospitalisation for heart failure than those assigned to receive placebo. The trial showed no significant differences, between dapagliflozin and placebo, in the risks of major adverse cardiovascular events (MACE) such as heart disease, stroke from blood clots or death from cardiovascular disease. [url="http://www.diabetes.co.uk/news/2019/oct/us-approves-farxiga-to-reduce-heart-failure-hospitalisation-risk-for-people-with-type-2-diabetes-97298463.html"]Continue reading...[/url] [/QUOTE]
Verification
Post Reply
Home
Forums
Diabetes News and Research
Diabetes News
US approves Farxiga to reduce heart failure hospitalisation risk for people with type 2...
Top
Bottom
Find support, ask questions and share your experiences. Ad free.
Join the community »
This site uses cookies. By continuing to use this site, you are agreeing to our use of cookies.
Accept
Learn More.…
